Japanese asthma patient's beta2 adrenaline-receptor geno type Arg16Gly cross-over trial about the effect of Salmeterol or Montelukast
Not Applicable
- Conditions
- Bronchial asthma
- Registration Number
- JPRN-UMIN000001635
- Lead Sponsor
- Hokkaido University Graduate School of Medicine Department of Internal Medicine ,Division or Respiratory Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1 Patients with allergy to Montelukast or Salmeterol 2 Patients with active respiratory infections 3 Pregnant or lactating patients 4 Patients with smoking index 200 or more than 200,or current smokers 5 Patients with other pulmonary complications. 6 Patients judged to be inappropriate by respirologists.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of the change in peak flow values over 4 months between the two groups who will be receiving salmeterol plus Inhaled corticosteroid (ICS) and who will be receiving montelukast plus ICS, based on stratification of beta2-adrenergic receptor gene pormorphism (Arg/Arg vs Gly/Gly)
- Secondary Outcome Measures
Name Time Method Comparison of the change in peak flow values between the two groups, (Arg/Arg vs. Gly/Gly) in the period when receiving salmeterol plus ICS Comparison of the change in peak flow values between the two groups, (Arg/Arg vs. Gly/Gly) in the period when receiving montelukast plus ICS The other outcome measurements include asthma control test, peripheral eosinophil count, and pulmonary function parameters